Prescribing information

 

__________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________

You can access the MAYZENT risk management resources below, which will help you initiate and manage your SPMS patients.

If you would like to receive printed copies of any of these materials, please contact your local MAYZENT key account manager.

 

Thumbnail of prescribers checklist.
 

PRESCRIBER’S CHECKLIST

A checklist of important points to remember before, during and after treatment with MAYZENT.

The link below link will take you to the electronic medicines compendium (emc) website, which is a non-Novartis website.

View

 

Thumbnail of summary of product characteristics for Mayzent.
 

SUMMARY OF PRODUCT CHARACTERISTICS FOR MAYZENT

Summary of product characteristics for MAYZENT.

The ‘view’ link below will take you to the electronic medicines compendium (emc) website, which is a non-Novartis website.

View  Download

 

Thumbnail of Mayzent pregnancy card.
 

MAYZENT PATIENT AND CAREGIVER GUIDE

A guide detailing important information about MAYZENT for patients and caregivers.

The ‘view’ link below will take you to the electronic medicines compendium (emc) website, which is a non-Novartis website.

View

 

 

Thumbnail of Mayzent patient and caregiver guide.
 

MAYZENT PREGNANCY CARD

A card detailing information for female patients of childbearing potential.

The ‘view’ link below will take you to the electronic medicines compendium (emc) website, which is a non-Novartis website.

View

 

Indication: MAYZENT is indicated for the treatment of adult patients with SPMS with active disease evidenced by relapses or imaging features of inflammatory activity.1

SPMS, secondary progressive multiple sclerosis.

Reference:

  1. MAYZENT (siponimod) Summary of Product Characteristics.
Rate this content: 
No votes yet
UK | June 2021 | 103440
×

Ask Speakers

×

Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at www.report.novartis.com
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]